RHYTHM PHARMACEUTICALS, INC. Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) of -$33.72 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes
us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease · last filed 2026-02-26
- RHYTHM PHARMACEUTICALS, INC. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2025 was -$33.72M.
- RHYTHM PHARMACEUTICALS, INC. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2024 was -$23.20M.
- RHYTHM PHARMACEUTICALS, INC. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2023 was -$12.16M.
- RHYTHM PHARMACEUTICALS, INC. accounts receivable, allowance for credit loss, period increase (decrease) for fiscal 2022 was -$1.33M.
| Period end | Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) 12 month |
|---|---|
| 2025-12-31 | -$33.72M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$23.20M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$12.16M 10-K · filed 2025-02-28 |
| 2022-12-31 | -$1.33M 10-K · filed 2024-02-29 |
| 2021-12-31 | -$95.00K 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |